Compare FOFO & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FOFO | ATYR |
|---|---|---|
| Founded | 2017 | 2005 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.2M | 79.2M |
| IPO Year | 2025 | 2015 |
| Metric | FOFO | ATYR |
|---|---|---|
| Price | $6.26 | $0.72 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.75 |
| AVG Volume (30 Days) | 78.6K | ★ 2.0M |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $3,117,608.00 | $190,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $18,728.88 |
| P/E Ratio | $16.64 | ★ N/A |
| Revenue Growth | ★ 1597.65 | N/A |
| 52 Week Low | $4.53 | $0.64 |
| 52 Week High | $68.00 | $7.29 |
| Indicator | FOFO | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 42.81 |
| Support Level | N/A | $0.71 |
| Resistance Level | N/A | $0.76 |
| Average True Range (ATR) | 0.00 | 0.05 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 0.00 | 20.29 |
Hang Feng Technology Innovation Co Ltd is committed to providing comprehensive corporate management consulting and asset management services, tailored to address the specific needs of each client. Its goal is to empower its clients to design, implement, and achieve their unique business and investment objectives. Its business consists of two main segments: (i) corporate management consulting services and (ii) asset management services. The corporate management consulting services include Management consulting, and Regulatory compliance and governance consulting.
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.